3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Carcinoma, Renal Cell
3
Virus Diseases
1
Urinary Bladder Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma in Situ
1
Adenoviridae Infections
1
Interventions
pembrolizumab
51
Nivolumab
27
Gemcitabine
23
atezolizumab
19
Cisplatin
18
Carboplatin
18
enfortumab vedotin
15
avelumab
15
Mitomycin
14
Docetaxel
8
Ipilimumab
7
Paclitaxel
6
Injections
5
Cyclophosphamide
5
vinflunine
4
toripalimab
4
tislelizumab
4
lenvatinib
4
fludarabine
4
epacadostat
4
Pemetrexed
4
130-nm albumin-bound paclitaxel
4
sacituzumab govitecan
3
disitamab vedotin
3
Rogaratinib
3
Interleukin-2
3
ALT-803
3
vofatamab
2
valrubicin
2
rucaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Transitional Cell
×
Interferons
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled